Fluoroquinolone Academic Research Update – Dr. Mark Noble, Part #1

Note: This is Part 1 of a two part series covering academic research with Dr. Mark Noble of the University of Rochester. 
This article, Part 1, covers both background and current research with Dr. Noble.

Part 2 . In his own words Dr. Noble reports on disturbing Levaquin toxicity findings he made in 2010 after our FQ team initiated research with him.

It goes without saying that academic research is vitally important to the fluoroquinolone (FQ) community and our goal to reveal the true impact that FQs are having on our society.

In this critical area of academic research, Dr. Mark Noble of the University of Rochester was one of three major academic researchers that saw the true impact of FQ toxicity and agreed to work with us on behalf of the FQ community. Dr. Noble is a delightfully altruistic and a talented professional. University_of_Rochester_seal_Small

Dr. Noble is Professor of Neurology, Genetics, and Neurobiology and Anatomy at University of Rochester School of Medicine and is Director of the University of Rochester Stem Cell and Regenerative Medicine Institute. He is one of the pioneers of stem cell research and directs research on multiple topics, including spinal cord injury, genetic diseases and cancer.


Our team initially contacted Dr. Noble in 2010 due to his research with chemotherapeutic pharmaceuticals such as 5FU, chemo brain, and the capabilities of his lab. After we presented Dr. Noble with some interesting scientific Levaquin, Dr. Noble agreed to perform initial lab tests using Levaquin.

In the fall of 2010, Dr. Linda Martin and Dr. Paul Schnipelsky, a retired pharmaceutical researcher and executive with PhD’s in Chemistry, traveled to meet Dr. Noble at his U of R lab. At this meeting, Dr. Noble presented results of his initial research. The results were very interesting indeed. I will soon be releasing this initial toxicity information on Levaquin that was produced by Dr. Noble in the fall of 2010.

The initial meeting between Dr. Noble, Dr. Schnipelsky, and Dr. Martin, combined with Dr. Noble’s initial findings, has led to a long standing working relationship that has included regular phone conferences attended by science professionals from within the FQ community. We are very pleased that our initial contact with Dr. Noble in 2010 was the impetus for his FQ research today.

Current Research Directions

We recently held a planned phone conference with Dr. Noble to get an update on various aspects of his FQ research. Mark-Noble

• Dr. Noble is currently preparing mice that are phenotypically predisposed with higher TNF (Tumor Necrosis Factors). These mice will be used to identify atypical inflammation involved in both muscular/skeletal and CNS issues. These mice will be used to study inflammatory patterns in FQ exposure.

• Dr. Noble has deferred lysosomal FQ related mouse experiments initially planned in the fall of 2014, pending further data collection. Because Dr. Noble still feels strongly that lysosomal issues play an important part in FQ toxicity, he has asked our group to collect data regarding certain specific symptoms possibly experienced by floxies that are directly related to lysosomal issues. This is something that we will begin soon.

• Dr. Noble has assisted us with a submission for the upcoming FDA Meeting.

Much has been happening in the FQ community on many fronts from the media, to the FDA, to research. Sometimes information, especially on the internet, moves at a frenetic pace and the facts get distorted or lost in the translation.

It is vitally important for the FQ community to have true, factual data regarding these issues in order to appear credible and stay well informed.

Our FQ team, which is the same team that solicited Dr. Noble in 2010, will continue to work closely with Dr. Noble, to bring you factual information on his academic FQ research.

Stay tuned to My Quin Story as I will be sure to inform the FQ community of any pertinent developments with Dr. Noble, Dr. Golomb, and Dr. Bennett.

You can read part 2 of this article, here.



David was damaged by fluoroquinolones in 2007 at age 46. Prior to, a healthy law enforcement official. Now an amateur FQ researcher, author, and commentator contributing to case studies and published papers on the FQ’s in the BMJ, European Journal of Medicine, The Journal of Community and Supportive Oncology, Oxford Academic Clinical infectious Diseases, and contributed data to many more.

3 Responses

  1. Diane says:

    Thank you for all that you are doing. I am curious, I read on a FB group that the QVF is working with Dr. Noble as well. Are you working with the QVF? or are both of you working separately with Dr. Noble?

    • Admin says:

      Diane, thank you for your comment and question. No, I am not working with the QVF, unfortunately at this time I do not support that organization for numerous reasons that I have articulated here. http://www.myquinstory.info/why-i-have-withdrawn-support-from-the-qvf/

      This may be hard to get across tactfully, but the QVF does not have any research projects with Dr. Noble. What you read is a matter of semantics. Some folks from the QVF recently queried Dr. Noble about his current FQ research, that’s all. Asking about their science and actually having science personnel actually participating with researchers are two different things.

      The QVF likes to believe that they have a mouse study that they somehow initiated with Dr. Noble in the fall of 2014. I was present on the call and they did not initiate the study. To get factual, the fall 2014 call encompassed Dr. Noble starting research on the FQ’s effects on lysosomal functioning. He initiated this on his own. At that time he was going to get some mice that have predisposed lysosomal weaknesses. That direction has since been tabled pending further data collection, which we are now collecting some preliminary data for.

      He is now starting a new study using mice with predisposed inflammation markers (TNF) that are going to be used to identify novel or atypical inflammation caused by FQ’s. Our FQ group is working Dr. Noble regarding this, just like we have with other areas. We have been working with Dr. Noble since 2010, not with one study, but with several.

      The QVF had, at one time, raised money for the University of Rochester (why I do not know since you can donate to the University directly and I was not involved by that time). They also donated some money for FQ research. However, they have not initiated, nor are they actively participating in any FQ research at the U of R.

      Some of this may sound like sour grapes, but I assure you it is not. Again please read my article to fill yourself in on the background. It is about being factual, setting the record straight, and working together. Sadly, I do not believe all the QVF members are fully aware of everything, as the first director and founder of the QVF, I am pretty sure they are not. Anyway, space and time prohibits me from elaborating why I was on the call in Nov. of 2014, and all the other intricacies. I am however very open and honest about what transpired and would be willing to discuss it with you privately. Just send me a PM or email and we speak.

      Setting all that unpleasantry aside, I am happy to say that research is on track with Dr. Noble, as well as others, and great things are happening across the board.

  2. Traci says:

    As an X QVF ambassador I agree with David. The red flags were there from the beginning and only got worse. I don’t regret leaving at all.

Leave a Reply

Your email address will not be published. Required fields are marked *

WordPress Anti Spam by WP-SpamShield